

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

**NICE Technology Appraisal No.377; Enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy, No.387; Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and No.391; Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel**

### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Astellas</li> <li>• Sanofi Genzyme</li> <li>• Janssen</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency</li> <li>• Bob Champion Cancer Trust</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Everyman</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• Muslim Council of Britain</li> <li>• Orchid</li> <li>• PCaSO - Prostate Cancer Network</li> <li>• Pelican Cancer Society</li> <li>• Prostate Cancer UK</li> <li>• Prostate Help Association</li> <li>• Robin Cancer Trust</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tackle Prostate Cancer</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Prostate Group</li> </ul>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparators</u></p> <ul style="list-style-type: none"> <li>• Accord (mitoxantrone)</li> <li>• Alliance Pharma (prednisolone)</li> <li>• Bayer (Radium 223dichloride)</li> <li>• Baxter (mitoxantrone)</li> <li>• Pfizer (mitoxantrone)</li> <li>• Wockhardt UK (prednisolone)</li> <li>• Zentiva UK (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Genomics England</li> </ul>

NICE Technology Appraisal No. 377; Enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy, No.387; Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and No.391; Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

<ul style="list-style-type: none"> <li>• British Geriatrics Society</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> <li>• Pelican Cancer Foundation</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Prostate Cancer Advisory Group</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Leeds South and East CCG</li> <li>• NHS Salford CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Ovarian and Prostate Cancer Research Trust</li> <li>• Pro Cancer Research Fund</li> <li>• Prostate Cancer Research Centre</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.